Kissei/JCR’s Nesp Biosimilar Shows Equivalence in Japan PIII

January 18, 2018
Kissei Pharmaceutical and JCR Pharmaceuticals said on January 17 that JR-131, their biosimilar version of Kyowa Hakko Kirin’s renal anemia agent Nesp (darbepoetin alfa) demonstrated its equivalence in efficacy versus the originator drug in a Japan PIII study. The two...read more